Clinical Trial Update: Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence [Phase 3]

View source ↗

Summary

Phase 3 trial of NeuVax (nelipepimut-S) to prevent breast cancer recurrence in patients with low-to-intermediate HER2 expression has completed; this update repo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• NeuVax (nelipepimut-S)

Snippet

Sponsor: Galena Biopharma, Inc. | Conditions: Breast Cancer With Low to Intermediate HER2 Expression | Phase 3 | Status: COMPLETED